首页> 外文OA文献 >WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on health-related quality of life (HRQoL) in people with cystic fibrosis (pwCF) homozygous for F508del (F/F): results from a Phase 3 clinical study

【2h】

WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on health-related quality of life (HRQoL) in people with cystic fibrosis (pwCF) homozygous for F508del (F/F): results from a Phase 3 clinical study

机译：WS19.6 Elexacaftor / Tezacaftor / Ivacafeafer（ELX / TEZ / IVA）三重组合治疗对囊性纤维化（PWCF）纯合（F / F）纯合的生育质量（HRQOL）的影响：结果第3阶段临床研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
C. Majoor; K. Van Brunt; C. Daines; I. Durieu; I. Fajac; J. Goralski; H. Heijerman; C. Knoop; J. Booth; S.M. Moskowitz; J. Savage; C. Wang; A. Quittner;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial (vol 394, pg 1940, 2019) [J] . The Lancet . 2020,第10238期

机译：Elexacaftor Plus Tezacaftor Plus invacafactor组合方案对F508del突变的囊性纤维化纯合的疗效和安全性：双盲，随机，第3阶段试验（Vol 394，PG 1940,2019）
2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [J] . Heijerman Harry G. M., McKone Edward F., Downey Damian G., The Lancet . 2019,第10212期

机译：Elexacafactor Plus Tezacaftor的功效和安全性Plus Ivacaftor组合中的人们在囊性纤维化纯合的F508del突变中：双盲，随机，第3阶段试验
3. PHASE 3 EFFICACY AND SAFETY OF THE ELX/TEZ/IVA TRIPLE COMBINATION IN PEOPLE WITH CF HOMOZYGOUS FOR THE F508DEL MUTATION [J] . Heijerman H., McKone E., Downey D. G., Pediatric Pulmonology . 2019,第Suppla2期

机译：ELX / TEZ / IVA三重组合在F508del突变中纯合的ELX / TEZ / IVA三重组合的疗效和安全性
4. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor [O] . Alice Tsai, Shu-Pei Wu, Eric Haseltine, 2020

机译：囊性纤维化转换从单组合Elexacafer / Tezacaftor / Ivacafacter / Ivacafacter / Ivacafacter / Ivacafacter / Ivacafacter患者CFTR调制的生理基础药代动力学建模
5. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial [O] . Harry G M Heijerman, Edward F McKone, Damian G Downey, 2019

机译：Elexacafactor Plus Tezacaftor的功效和安全性Plus Ivacaftor组合中的人们在囊性纤维化纯合的F508del突变中：双盲，随机，第3阶段试验

WS19.6 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on health-related quality of life (HRQoL) in people with cystic fibrosis (pwCF) homozygous for F508del (F/F): results from a Phase 3 clinical study

著录项

引文网络

相似文献

相关主题

期刊订阅